Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

1.380 -0.030 (-2.13%)
Official Closing Price Updated: 8:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198,831
Open 1.360
Bid (Size) 1.350 (4)
Ask (Size) 1.390 (5)
Prev. Close 1.410
Today's Range 1.340 - 1.390
52wk Range 1.020 - 1.790
Shares Outstanding 170,145,713
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics's Return On Capital Employed Overview
 
Via Benzinga

Performance

YTD
+12.20%
+12.20%
1 Month
+9.52%
+9.52%
3 Month
+13.11%
+13.11%
6 Month
+13.11%
+13.11%
1 Year
+1.47%
+1.47%

More News

Read More
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Preview: Lineage Cell Therapeutics's Earnings
Via Benzinga
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
From Lineage Cell Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology
Via Benzinga
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Preview: Lineage Cell Therapeutics
Via Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Via TheNewswire.com
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Via News Direct
121 Stocks That Hit Their 52-Week Low
Via Benzinga
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Via Benzinga
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.